Orthocell Ltd (ASX:OCC, OTC:ORHHF) has achieved first commercial sales of its flagship nerve repair device Remplir™ in Canada, marking the start of revenue generation in the country’s estimated US$75 ...
An announcement from Orthocell Ltd ( (AU:OCC)) is now available. Orthocell Ltd has applied to the ASX for quotation of 217,742 new fully paid ordinary shares under its ticker OCC. The additional ...
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has reported an 89.7% overall treatment success rate from its ongoing Remplir™ Real World Evidence study, supporting the company’s US commercial rollout and planned ...
Small caps are heading into a firmer session, with ASX futures pointing higher after another strong Wall Street lead, as easing oil prices and renewed hopes for US–Iran talks continue to support risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results